




>>>**Entry Name:** Fluvastatin, BAN, INN

Synonym(s): 7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1*H*-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, 9CI. 7-[3-(4-Fluorophenyl)-1-isopropyl-2-indolyl]-3,5-dihydroxy-6-heptenoic acid. Canef. Cranoc. Fluindostatin. Fractal. Lescol. Lipaxan. Locol. Lymetel. Primesin. Vastin. XU 62-320



CAS Registry Number: 93957-54-1

Related CAS Registry Numbers(s): 126872-01-3

Molecular Formula: C₂₄H₂₆FNO₄

Molecular Weight: 411.472

Accurate Mass: 411.184587

Percentage Composition: C 70.06%; H 6.37%; F 4.62%; N 3.40%; O 15.55%

Biological Use/Importance: Potent HMG-CoA reductase inhibitor; used as an antihyperlipidaemic agent

Development Status: Marketed drug. Launched 1994 (UK)

Calculated Log P Data: Log P 3.16 (calc)

Other Data: Stereochem. is (3*R*,5*S*,6*E*)

>>>**Derivative:** Na salt

Synonym(s): Fluvastatin sodium, USAN

CAS Registry Number: 93957-55-2

References:

- Eur. Pat.*, 1987, Sandoz, 244 364; *CA*, **108**, 131038q, (*synth, pharmacol*)
Tse, F.L.S. *et al.*, *Biopharm. Drug Dispos.*, 1990, **11**, 519, (*metab*)
Kathawala, F.G., *Med. Res. Rev.*, 1991, **11**, 121, (*rev*)
Tse, F.L.S. *et al.*, *J. Clin. Pharmacol.*, 1992, **32**, 630, (*pharmacokinet, human*)
Dain, J.G. *et al.*, *Drug Metab. Dispos.*, 1993, **21**, 567, (*metab, human*)
Kalafsky, G. *et al.*, *J. Chromatogr.*, 1993, **614**, 307, (*hplc*)
Brown, W.V., *Am. J. Cardiol.*, 1994, **73**, 1D; 12D; 18D, (*rev*)
Shiomi, M. *et al.*, *Arzneim.-Forsch.*, 1994, **44**, 1154, (*pharmacol*)
Robison, R.L. *et al.*, *Fundam. Appl. Toxicol.*, 1994, **23**, 9, (*tox*)
Plosker, G.L. *et al.*, *Drugs*, 1996, **51**, 433, (*rev*)
Drugs of Today (Barcelona), Suppl. A, (Fluvastatin), 1996, **32**, (*rev, pharmacol, pharmacokinet*)
Langtry, H.D. *et al.*, *Drugs*, 1999, **57**, 583-606, (*rev*)
Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 1273